GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Cash Receipts from Operating Activities

Aclaris Therapeutics (FRA:8AT) Cash Receipts from Operating Activities


View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Cash Receipts from Operating Activities?

Cash Receipts from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Aclaris Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.